#None #UCB #Antengene #ATG-201

Antengene and UCB Join Forces in Groundbreaking License Agreement for ATG-201

In a significant move within the biopharmaceutical sector, Antengene Corporation Limited has finalized a global license agreement with UCB for the development of ATG-201, a bispecific T-cell engager (TCE) specifically designed to target autoimmune diseases.

Overview of the Agreement

Antengene has granted UCB exclusive worldwide rights to further develop, manufacture, and commercialize ATG-201, which focuses on targeting B cell-mediated autoimmune disorders. This partnership expects to yield an immediate financial gain of $80 million for Antengene through upfront and near-term milestone payments. Furthermore, Antengene stands to gain over $1.1 billion based on the success of future development, regulatory, and sales milestones, in addition to tiered royalties from future net sales.

What is ATG-201?

ATG-201 leverages a unique CD19/CD3 bispecific T-cell engaging mechanism, designed to specifically eliminate B cells that express the CD19 marker. These B cells are often implicated in various autoimmune diseases and some hematological cancers. The innovation behind ATG-201 lies in its use of steric hindrance masking technology, which maximizes the efficacy of B cell depletion while minimizing adverse reactions, such as cytokine release syndrome (CRS).

By integrating its proprietary CD3 sequence, ATG-201 activates the body’s immune system to tackle diseases more effectively, marking a new frontier in immunotherapy.

Collaboration Highlights

Both companies emphasize that this collaboration harnesses Antengene's advanced TCE platform, AnTenGager™, combined with UCB’s robust immunology expertise. According to Dr. Jay Mei, Antengene's Founder and CEO, this partnership not only aims to expedite the development of ATG-201 but also signifies the platform’s capacity to deliver novel therapeutics across various medical needs.

UCB’s Chief Scientific Officer, Alistair Henry, expressed enthusiasm for this collaboration, noting it enhances UCB's commitment to innovation in immunology while expanding their portfolio in bispecific T-cell engagers. This deal also aligns with UCB’s strategy of integrating cutting-edge technology into their biologics pipeline, reinforcing their leadership in developing new treatment modalities for immunological conditions.

Future Directions

Antengene is poised to submit clinical trial applications for ATG-201 in China and Australia by the first quarter of 2026. They plan to conduct first-in-human phase 1 studies in these territories, from which results will inform the progression of clinical development and eventually be handed over to UCB for wider commercialization efforts.

As this partnership unfolds, Antengene’s capabilities and prior intellectual property in the field of T-cell engagers can lead to the development of multiple innovative therapies not only for autoimmune diseases but also for targeting solid tumors and hematological malignancies.

Closing Thoughts

The agreement between Antengene and UCB represents a notable advancement in the field of biopharmaceuticals, particularly in the domain of immunotherapy for autoimmune conditions. It’s a testament to how collaboration across innovative platforms and expert knowledge in the sector can accelerate drug development and tackle complex health challenges effectively. As Antengene continues to drive forward with its ambitious pipeline, observers will be keen to see how ATG-201 can redefine treatment pathways for autoimmune diseases.

For more updates, follow the upcoming conference call and webcast scheduled for March 4, 2026.